Drug Research and Development Experts form Michigan CMC Alliance
(March 31, 2009; Kalamazoo, MI)-Several Michigan companies have formed a strategic alliance centered around pharmaceutical chemistry, manufacturing and control development (CMC), aptly called the Michigan CMC Alliance. This alliance is comprised of contract service providers, each an expert in a distinct component in the drug development spectrum, from preclinical to clinical phases and regulatory submission/approval.
Member organizations each have a firm foundation of experience and expertise within the pharmaceutical industry along with a scientific infrastructure to deliver cost-effective, compliant results. The ability to leverage the intellectual capital resident within each organization is a distinct advantage to those in need of pharmaceutical CMC resources and expert strategies for comprehensive drug development.
The Michigan CMC Alliance brings together the forces of:
· Ash Stevens, Inc.: GMP AP development and manufacturing
· BioSTAT Consultants:Statistical services: design and analysis
· Eurofins AvTech Laboratories, Inc.:GMP and GLP analytical services
· Global Clinical Connections, LLC: Clinical supplies management
· Pharmaceutical Development Consulting, LLC: Formulation Development & Project Management
· PharmaMed Resources, LLC: Quality assurance
· ProReg Resources, LLC:Regulatory consulting services
· Velesco Pharmaceutical Services: Formulation, analytical development and GMP manufacturing
“There is an abundance of pharma industry knowledge within Michigan; niche experts in each phase or components necessary to propel a drug forward through the development process. It seemed a natural fit to combine our forces in a strategic alliance,” stated Bill Pfund, a Director at Eurofins AvTech Laboratories. “Each company shares a common mission and vision along with a dedication to delivering quality, on-time results with the highest degree of scientific integrity.”
Additional information on the Michigan CMC Alliance can be found at www.micmcalliance.com or by contacting 269-267-7290.
About Michigan CMC Alliance
Michigan CMC Alliance’s mission is to support the growth and success of life science companies everywhere by providing CMC resources and expert strategies to drug development, as well as, education on the complexities of the CMC development process. Utilizing years of experience and a complete understanding of the intricate drug development process, our member companies partner with clients and each other to deliver compliant, effective solutions that drive projects to success, on-time and within budget.
About Eurofins AvTech Laboratories
Eurofins AvTech is an analytical contract research organization (CRO) serving the pharmaceutical industry since 1990. AvTech offers comprehensive analytical support for all stages of drug discovery and development from early ADME studies of drug candidates, to stability and release testing of the finished product. Eurofins AvTech places special emphasis on the development, validation, and routine performance of GMP and GLP compliant methods.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
